Life ScienceCompany
ADVANZ PHARMA M&A Summary
ADVANZ PHARMA has acquired 6 companies of its own, including 2 in the last 5 years. A total of 1 acquisition came from private equity firms. It has also divested 1 asset.
ADVANZ PHARMA’s largest acquisition to date was in 2015, when it acquired Amdipharm Mercury - AMCo. for $3.5B. It’s largest disclosed sale occurred in 2015, when it sold Concordia Pharmaceuticals - Frotaz Zinacef ad Zantac Injection to Teligent for $10M. ADVANZ PHARMA has acquired in 3 different US states, and 4 countries. The Company’s most targeted sectors include life science (67%) and healthcare services (17%).
ADVANZ PHARMA Ownership
Who owns ADVANZ PHARMA?
ADVANZ PHARMA is owned by Nordic Capital. It was acquired on January 27, 2021.
Is ADVANZ PHARMA PE-backed?
Yes. ADVANZ PHARMA is owned by private equity investor Nordic Capital.
ADVANZ PHARMA Business Overview
Where is ADVANZ PHARMA headquartered?
ADVANZ PHARMA is headquartered in London, United Kingdom.
What is ADVANZ PHARMA’s revenue?
ADVANZ PHARMA disclosed revenue of 508M USD for 2019 and 537M USD for 2018.
How many employees does ADVANZ PHARMA have?
ADVANZ PHARMA has 630 employees.
What sector is ADVANZ PHARMA in?
ADVANZ PHARMA is a life science company.
M&A Summary
-
M&A Total Activity7
- M&A Buy Activity6
- M&A Sell Activity1
- Total Sectors Invested 3
- Total Countries Invested 4
- M&A Buy/Sell Connections 4
- M&A Advisors 7
Unlimited Searches
